|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The International Myeloma Working Group has defined smoldering multiple myeloma (SMM) as the presence of 10%-60% plasma cells in the bone marrow and M-protein (IgG, IgA) ≥3 g/dL without end-organ damage (an increased calcium level, renal failure, anemia, and destructive bone lesions).
|
31842112 |
2020 |
|
Rheumatic Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Humoral immunity in response to M protein, an antigen implicated in ARF pathogenesis, was completely polarized to IgG3 in the patient group.
|
31742781 |
2020 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.
|
31399530 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty five percent of MM patients are under the age of 65, 28% are between 65 and 74 of age and 37% are over the age of 75.<sup>5</sup> Pathophysiological mechanisms of MM include abnormal plasma cells (myeloma cells) occupying bone marrow, producing monoclonal immunoglobulin (M protein, M-component, and paraprotein) and increased bone destruction.<sup>6</sup> Breast cancer cases diagnosed concurrently with myeloma have been reported in previous case reports.
|
30738577 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes (POEMS) syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm.
|
31012139 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
People with MM will have damaged organs or tissues due to secretion of large amounts of monoclonal immunoglobulin or fragments (M protein).
|
29212572 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of myeloma progression (PD) relies on serial 24-h urinary M protein measurements in patients without measurable serum M spike.
|
30016549 |
2018 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients (≥20 years) with measurable secretory multiple myeloma (serum monoclonal IgG ≥10, IgA/IgE ≥5, IgD ≥0.5 g/L, IgM present [regardless of level], and urine M protein of ≥200 mg/24 h) received intravenous bortezomib 1.3 mg/m<sup>2</sup> , twice weekly for 2 weeks, followed by a 10-day resting phase (days 12 to 21).
|
28626947 |
2018 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated flow cytometric CD19 and CD45 expression, DNA ploidy index and M-protein subtype in 416 t(11;14)-positive PCNs, as well as control groups (88 BCL-PCDs and 81 t(11;14)-negative PCNs).
|
29214874 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate analysis identified the presence of M protein as a potential risk factor for the secondary occurrence of myelofibrosis (p = .02), myelodysplastic syndrome (p = .043), and MM/Waldenstrom macroglobulinemia (p < .0001).
|
28482711 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifty-nine of 103 patients with M-protein level < 3000 mg/dL in serum or 500 mg/24 h in urine and diagnosed with monoclonal gammopathy of undetermined significance (MGUS) based on smear alone were reclassified as smoldering MM when reassessed using CD138-stained biopsy/clot sections.
|
27140172 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified intercriteria dependences that are general for the various types of MM and thus can be regarded as a characteristic of this largely heterogeneous disease: strong contribution of the monoclonal (M) protein concentration to the excess heat capacity of the immunoglobulins-assigned thermal transition; shift of the albumin assigned calorimetric transition to allocation where it overlaps with the globulins assigned transition and strong shift of the globulins assigned transition temperature attributable to M proteins conformational changes.
|
27751955 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This resulted in a complete remission of the myeloma with disappearance of the M-protein.
|
27516004 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma.
|
28841203 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine.
|
27718532 |
2017 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We sought to investigate relationship between elevated serum M protein levels and echocardiographic indices of cardiac structure and function in patients with MM.
|
27048256 |
2017 |
|
Rheumatic Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
S. pyogenes M protein is the major virulence factor, and certain regions of its N-terminus can trigger autoimmune sequelae such as rheumatic fever in susceptible individuals with untreated group A streptococcal pharyngitis.
|
23593359 |
2013 |
|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
The combination of a genome-wide association study of lymphocyte count and analysis of gene expression data reveals novel asthma candidate genes.
|
22286170 |
2012 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnosis of MM requires the presence of an M-protein in serum and/or urine, increased bone marrow plasma cells and related organ or tissue impairment.
|
20943635 |
2010 |
|
Rheumatic Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified several M protein epitopes recognized by peripheral T cells of RF/RHD patients and by heart tissue infiltrating T cell clones of severe RHD patients.
|
17305559 |
2007 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increased level of serum M-protein IgG may affect the growth or survival of myeloma cells through the Fcgamma inverted exclamation mark receptor (FcgammaR) in human myelomas.
|
16818279 |
2006 |
|
Rheumatic Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.
|
17172649 |
2006 |
|
Rheumatic Fever
|
0.100 |
Biomarker
|
disease |
BEFREE |
Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States.
|
16421785 |
2006 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two variants of smoldering multiple myeloma (SMM) have been recognised: (i) an evolving type, characterised by a progressive increase in the M-protein size and short time to progression to overt multiple myeloma (MM) and (ii) a non-evolving type, with a long-lasting, stable M-protein and longer time to progression.
|
16115129 |
2005 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple myeloma (MM) is identified by unique immunoglobulin heavy chain (IgH) variable diversity joining region gene rearrangements, termed clonotypic, and an M protein termed the "clinical" isotype.
|
11675353 |
2001 |